Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

Basit Öğe Kaydı
dc.authoridReck, Martin/0000-0002-5348-4462;
dc.authorwosidReck, Martin/ABF-5721-2020
dc.authorwosidliu, qi/KFA-4047-2024
dc.authorwosidPoddubskaya, Elena/AAK-7600-2021
dc.authorwosidLiu, Yinuo/IZD-6086-2023
dc.contributor.authorSelvaggi, G.
dc.contributor.authorWakelee, H. A.
dc.contributor.authorMok, T.
dc.contributor.authorWu, Y. -L.
dc.contributor.authorReck, M.
dc.contributor.authorChiappori, A.
dc.contributor.authorCicin, I.
dc.date.accessioned2024-06-12T10:51:10Z
dc.date.available2024-06-12T10:51:10Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageE42en_US
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10en_US
dc.identifier.startpageE41en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18272
dc.identifier.volume15en_US
dc.identifier.wosWOS:000569266100003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofJournal Of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectALK Plus NSCLCen_US
dc.subjectEnsartiniben_US
dc.subjectCrizotiniben_US
dc.titlePhase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu